Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy in Treating Patients With Bladder Cancer

Study:

Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder

Rationale:

Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Purpose:

Randomized phase III trial to compare different combination chemotherapy regimens in treating patients who have advanced bladder cancer.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Bladder Cancer Biological: filgrastim
Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: gemcitabine hydrochloride
Phase 3

Verified by Alliance for Clinical Trials in Oncology September, 2013

Sponsored by: Alliance for Clinical Trials in Oncology
Information provided by: Alliance for Clinical Trials in Oncology
ClinicalTrials.gov identifier: NCT00014534

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States

Dean F. Bajorin, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site